Escherichia coli ST131: a multidrug-resistant clone primed for global domination [version 1; peer review: 2 approved]

• Published in: F1000 research Vol. 6; p. 195
• Main Authors: Pitout, Johann D.D, DeVinney, Rebekah
• Format: Journal Article
• Language: English
• Published: England Faculty of 1000 Ltd 2017; F1000Research; F1000 Research Ltd
• Subjects: Antimicrobial agents; Cellular Microbiology & Pathogenesis; Medical Microbiology; Microbial Evolution & Genomics; Multidrug resistant organisms; Review; Escherichia coli ST131; antimicrobial-resistant infection; ExPEC
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.10609.1

A single extra-intestinal pathogenic Escherichia coli (ExPEC) clone, named sequence type (ST) 131, is responsible for millions of global antimicrobial-resistant (AMR) infections annually. Population genetics indicate that ST131 consists of different clades (i.e. A, B, and C); however, clade C is the most dominant globally. A ST131 subclade, named C1-M27, is emerging in Japan and has been responsible for the recent increase in AMR ExPEC in that country. The sequential acquisition of several virulence and AMR genes associated with mobile genetic elements during the 1960s to 1980s primed clade C (and its subclades C1 and C2) for success in the 1990s to 2000s. IncF plasmids with F1:A2:B20 and F2:A1:B replicons have shaped the evolution of the C1 and C2 subclades. It is possible that ST131 is a host generalist with different accessory gene profiles. Compensatory mutations within the core genome of this clone have counterbalanced the fitness cost associated with IncF plasmids. ST131 clade C had dramatically changed the population structure of ExPEC, but it still remains unclear which features of this clade resulted in one of the most unprecedented AMR successes of the 2000s.